



Asociación
Colombiana de
Reumatología®

Revista Colombiana de REUMATOLOGÍA

www.elsevier.es/rcreuma



Case report

Schnitzler's syndrome: A diagnostic crossroads

Andrés Felipe Usma Valencia^{a,*}, Erwin Mauricio Giraldo Carmona^a,
Valentina Moreno Villegas Rojas^a, Soraya Villegas Rojas^a, Jorge Alejandro Castro^{a,b},
Lina María Saldarriaga Rivera^{a,b,c}

^a Grupo de Investigación en Medicina Interna, Universidad Tecnológica de Pereira, Pereira, Colombia

^b Departamento de Medicina Interna, Universidad Tecnológica de Pereira, Pereira, Colombia

^c Departamento de Medicina Interna y Reumatología, Universidad Tecnológica de Pereira, Pereira, Colombia

ARTICLE INFO

Article history:

Received 3 July 2022

Accepted 20 October 2022

Available online 18 May 2024

Keywords:

Schnitzler syndrome

Urticaria

Monoclonal gammopathy of

undetermined importance

Auto-inflammatory disorders

ABSTRACT

Schnitzler syndrome is a rare disease, in Colombia it is considered an orphan disease, of an auto-inflammatory nature, classified as a complex acquired inflammatory type of disease, which classically produces urticarial rash, long-standing fever, adenomegalies, and arthralgias coexisting with monoclonal gamma peak typically of the IgM type. We present the case of a young woman, with a larval picture that started with urticarial rash, with clinical characteristics compatible with the syndrome and evidence of monoclonal peak in protein electrophoresis meeting Lipsker-Baltimore 2001 criteria and Strasbourg 2013 criteria for diagnosis.

© 2022 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Síndrome de Schnitzler: una encrucijada diagnóstica

RESUMEN

El síndrome de Schnitzler es una enfermedad rara, en Colombia se la considera dentro de las enfermedades huérfanas, de carácter autoinflamatorio y se la clasifica como tipo inflamopatía adquirida compleja que produce clásicamente la presencia de rash urticarial, fiebre de larga data, adenomegalias y artralgias que coexisten con pico gamma monoclonal típicamente de tipo IgM. Se presenta el caso de una mujer joven, con cuadro larvado que inició con rash urticarial y características clínicas compatibles con el síndrome y evidencia de pico monoclonal en electroforesis de proteínas que cumple con los criterios de

Palabras clave:

Síndrome de Schnitzler

Urticaria

Gammopatía monoclonal de

importancia indeterminada

Trastornos autoinflamatorios

DOI of original article: <https://doi.org/10.1016/j.rcreue.2022.10.005>.

* Corresponding author.

E-mail addresses: andresfusma@utp.edu.co, andresfusma@gmail.com (A.F. Usma Valencia).

2444-4405/© 2022 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Lipsker-Baltimore 2001, así como con los criterios de Estrasburgo 2013 para el diagnóstico, y mejoría clínica tras la instauración de tratamiento inmunomodulador.

© 2022 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U.
Todos los derechos reservados.

Introduction

Schnitzler syndrome is a rare, chronic disorder categorized as autoinflammatory and classified within this spectrum as complex acquired inflammopathy.¹⁻³ The first case was described in 1972^{1,4,5} and, despite its distant description in the literature, there are still no more than 300 case reports, and it remains an unknown disorder in everyday medical practice.⁵ This disorder affects males with a slight predominance, with an average onset age of 40–50 years; yet great heterogeneity has been evidenced through case reports of subjects from adolescents to octogenarians.^{1,5,6} It is clinically characterized by the appearance of a recurrent non-pruritic urticarial rash, associated with a monoclonal gamma peak that may in turn be associated with chronic fever, lymphadenopathy, hepato or splenomegaly, and arthralgias with the presence of bone pain.^{6,7}

In 2001, the Lipsker-Baltimore diagnostic criteria were established, which were replaced in 2013 by the Strasbourg criteria. The latter have proven to be more practical in the clinical setting, since they only require the coexistence of 2 major criteria (chronic urticarial rash and IgM or IgG monoclonal gammopathy) and at least 2 minor criteria (intermittent fever, arthralgia or arthritis, bone pain, palpable lymphadenopathy, splenomegaly or hepatomegaly, elevated erythrocyte sedimentation rate, leukocytosis, and bone abnormalities).⁵

The pathophysiology has not been fully understood and attempts have been made to compare it with other autoinflammatory syndromes, including the cryopyridine-associated periodic syndrome, to elucidate the physiopathogenic mechanism, which is compatible with the dysregulation of innate immunity mediated by neutrophils and monocytes.^{3,9,11,13}

It has not been possible to determine a genetic basis that explains the etiology of the disease, but it is known that patients present a high secretion of cytokines such as IL-1 β and IL-6 by monoclonal cells, which constitutes a severity marker.⁵

In this sense, the elevation of cytokines has been correlated with the clinical manifestations of the disease, attributing its specific effects in different organs, in such a way that IL-1 β represents a signaling molecule that induces an increase in endogenous pyrogens in the central nervous system (specifically at the hypothalamus), with the subsequent elevation in body temperature and the fever characteristic of the syndrome.⁹

The increased production of IL-1 β by skin mast cells explains the presence of chronic urticaria in these individuals. The role of IgM monoclonal gammopathy has not yet been elucidated, as there is controversy over whether this finding is a cause or a consequence of the disorder. The most accurate hypothesis points to persistent stimulation of the

IL-1 receptor, which could lead to monoclonal production of IgM.¹

From this perspective, IL-1 β has been established as a pharmacological target, and good results have been obtained using the inhibitor anakinra, with remission levels of up to 83%.^{1,9,11} Canakinumab has also demonstrated adequate effectiveness in these subjects.¹ The use of other therapeutic measures such as corticosteroids, interferon alpha, and colchicine has moderate effectiveness and a high risk of adverse reactions; therefore, they have not been universally recommended.¹

The case of a young patient with chronic urticaria and subsequent clinical manifestations is presented, which, with the support of extension studies, led to the diagnosis of Schnitzler syndrome, a rare disease of which there is no documentation of local or national cases. Hence, it constitutes the first case report of a patient in which the diagnosis of Schnitzler syndrome is confirmed in Colombia based on the Strasbourg criteria.

As previously stated, knowledge of this disorder is relevant to broaden the diagnostic horizon and establish this nosological entity within the differential spectrum of the patient with a confluence of fever of unknown origin and skin lesions, specifically of the chronic urticarial type. Based on this, we aim to optimize the knowledge of an underestimated disease to make an earlier diagnosis, which allows establishing a timely treatment that avoids exposure to unnecessary medications and optimizes early therapy, so that it leads to a better outcome and prognosis, and to reduce morbidity and mortality.

Case presentation

A 26-year-old, mestizo female patient with a history of autoimmune thyroiditis who has been followed up by endocrinology for 6 years, presented with clinical symptoms of four months of evolution that began with urticarial rash in the lower limbs (Figs. 1A and B), a symptom that usually began in the afternoon and disappeared at night, without evidence of cutaneous stigmata in the next morning. Subsequently, these lesions spread to the upper limbs, torso, and face, with concomitant asthenia and adynamia. Due to this clinical picture, the patient initially consulted to dermatology and was diagnosed with urticaria, after which medical management with antihistamines was instituted, without any improvement.

Three months after the onset of these symptoms, the patient noticed arthralgias in the hands and wrists, which predominated upon waking up, accompanied by morning stiffness, without obvious inflammatory changes, but with marked improvement over the day. Subsequently, ostealgia in the anterior region of the tibia and lymphadenopathy in the cervical chain appeared, and she continued to experience periodic chills without any predominance of time,




Fig. 1 – AB - Presence of urticarial rash on the lower limbs. Images of own authorship, taken during medical consultation, for which informed consent was signed by the patient for publication in this case report.

which led to a new consultation, this time for internal medicine and rheumatology. As a result, extension studies and skin biopsy were requested, which reported histopathological changes compatible with urticaria, for which antihistamine management and short-course glucocorticoid therapy were optimized. Afterwards, she showed partial improvement, but with symptomatic resumption once the medication was withdrawn.

Afterward, the symptoms described were superimposed by the appearance of fever, which did not have a time-dependent

predominance, fluctuating, and initially yielded to the administration of common antipyretics. Finally, this febrile condition became continuous and reached fever peaks of up to 40°C, which led to consultation in the emergency room, and hospitalization in a tertiary care unit.

Upon admission, clear signs of a systemic inflammatory response were described, but with a qSOFA score of 0 and an adequate general appearance, without signs of tissue hypoperfusion, with soapy skin lesions distributed on the torso and extremities. During the hospital stay, the patient's symptoms persisted and there was febrile recurrence, despite management with antipyretics, initiating multiple broad-spectrum antibiotic management.

Multiple extension studies were performed, which are represented in Table 1, including a simple tomography (CT) of the chest, which showed 3.2 mm subpleural nodules in the middle and upper right lobes, possibly related to granulomas in formation, in addition to a computed axial tomography of the abdomen and pelvis, demonstrating hepatomegaly. Based on the above, a presumptive diagnosis of Still's disease was considered, but despite meeting major Yamaguchi criteria, such as fever greater than 39°C, arthralgia, leukocytosis greater than 10,000/mm³, and neutrophilia greater than 80%, plus some minor criteria (lymphadenopathy), there were elements against it, such as the presence of skin lesions, which are not those classically described, such as an evanescent salmon-like rash. Likewise, there was a positive rheumatoid factor result with ferritin and normal liver function tests, which made this hypothesis very unlikely, especially considering that Still's disease is a diagnosis of exclusion. A bone marrow study was conducted, which showed no pathological findings, as well as protein electrophoresis in serum and urine, which found a monoclonal gamma peak and immunofixation with a monotypic IgG peak, which in the patient's clinical context constituted the diagnosis of Schnitzler syndrome, meeting 2001 Lipsker-Baltimore and 2013 Strasbourg criteria (Tables 2 and 3). Once the diagnosis was confirmed, treatment with glucocorticoids was started in conjunction with azathioprine, calcium, and vitamin D, which resulted in the disappearance of the skin lesions, cessation of febrile peaks, and the resolution of arthralgias and ostealgias.

Discussion

Schnitzler syndrome is a rare acquired chronic autoinflammatory disease. The literature has reported around 300 cases in the world, few of them reported in Latin America.⁵ The disease manifests itself with urticarial rashes, fatigue, bone or joint pain, lymph node inflammation, and fever associated with monoclonal IgM type gammopathy; its pathophysiology is still not clear.^{1-3,5} The literature has reported an average age of 40–56 years, with a predominance in men.^{1,5,6} Our case, a young 26-year-old female patient, is a variation from what has been reported.

This case represented a diagnostic challenge due to the symptoms and the possibility of Still's syndrome; however, certain findings were unlikely related to this disorder, such as the presence of skin lesions, which are not classically described as an evanescent salmon-like rash. Additionally,

Table 1 – Paraclinical tests.

Lab test	Result	Lab test	Result
Leukocytes	12 k/mL	HBsAg	0.363 (negative)
Neutrophils	8.9 k/mL	LDH	210
Lymphocytes	1.5 k/mL	VDRL	Non-reactive
Hb	11.1 g/dl	HIV	Negative
Platelets	570,000	Procalcitonin	0.22
Creatinine	0.74 mg/dl	Ferritin	1801
AST	26 U/l	Amylase	78
ALT	46 U/l	Anti-Sm antibodies	5.3
TSH	4.7 mU/l	Anti-RNP antibodies (IgG)	< 3.0
T4	11.5 ng/dl	Anti-Ro antibodies (IgG)	< 3.0
T3	2.39 ng/dl	Anti-La antibodies (IgG)	< 3.0
CRP	12.3 mg/l	Anti-DNA antibodies	Negative
ESR	38 mm/h	Anti-thyroglobulin antibodies	51.11 (positive)
Alkaline phosphatase	117.0 U/l	Anti-microsomal thyroid peroxidase antibodies (anti-TPO)	124.88 (positive)
Immunoglobulin G	1508	Anti-CCP	Negative
Immunoglobulin A	206	C3	187
Immunoglobulin M	117	C4	18
Immunoglobulin E	131	IgG <i>Bartonella henselae</i>	Negative
IgM for dengue	Negative	IgG <i>Brucella abortus</i>	Negative
Rheumatoid factor	28	IgM Cytomegalovirus	Negative
Thick drop	Normal	Monotest heterophil antibodies	Negative
Anti-HCV	<0.9 (negative)		

ALT: alanine aminotransferase; AST: aspartate aminotransferase; anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-HCV: antibodies against hepatitis C virus; anti-TPO: anti-thyroid peroxidase antibodies; Hb: hemoglobin; HBsAg: hepatitis B surface antigen, LDH: lactate dehydrogenase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.

Source: Self-made.

Table 2 – 2001 Lipsker-Baltimore diagnostic criteria for Schnitzler syndrome.

Rash, hives, and monoclonal IgM component and at least 2 of the following criteria
Fever
Arthralgia or arthritis
Bone pain
Palpable lymph nodes
Enlarged liver or spleen
Elevated ESR
Leukocytosis
Abnormal findings in bone morphological investigations
ESR: Erythrocyte sedimentation rate.

there was a positive rheumatoid factor result with ferritin and normal liver function tests, which made this hypothesis very improbable. It should be noted that the combination of clinical, laboratory, and imaging findings was essential. The 2001 Lipsker-Baltimore and 2013 Strasbourg criteria were considered, in addition to the exclusion of other causes such as autoimmune hepatitis, but they were inconclusive due to normal liver function tests.

As mentioned previously, the pathogenesis of the disease is not very clearly known^{3-8,12}; different studies refer to an alteration of the cytokine balance of innate immunity; due to its recognition as an inflammatory disorder, current research has focused on the role of IL-1 β , hence immunosuppressants, such as corticosteroids, interferon α , cyclooxygenase inhibitors, anakinra (an IL-1 receptor antagonist), colchicine, cyclosporine, or thalidomide are used to control the disease.^{1,5,9-11,13} Due to its infrequency, there are

Table 3 – Strasbourg diagnostic criteria for Schnitzler syndrome.

Mandatory criteria
Chronic urticaria rash and monoclonal IgM or IgG
Minor criteria
Relapsing fever ^a
Objective findings of abnormal bone remodeling with or without pain ^b
Neutrophilic dermal infiltrate in skin biopsy ^c
Leukocytosis or elevated CRP ^d
Definitive diagnosis if
Two mandatory criteria and at least 2 minor criteria if it is IgM and 3 minor criteria if it is IgG
Probable diagnosis if
Two mandatory criteria and at least one minor criterion if it is IgM and 2 minor criteria if it is IgG

MRI: Magnetic resonance imaging; CPR: C-reactive protein.

^a It must be >38 °C and without any other explanation. It usually, but not necessarily, occurs along with the skin rash.

^b As assessed by bone scan, MRI, or bone alkaline phosphatase elevation.

^c It usually corresponds to the entity described as “neutrophilic urticarial dermatosis” (Medicine. 2009;88:23-31); absence of fibrinoid necrosis, and significant dermal edema.

^d Neutrophils > 10,000/mm³ and/or CRP > 30 mg/l.

still no studies that compare the effectiveness of the different treatments, nor has a standard therapeutic management been reported, which is why in our case we used glucocorticoids and azathioprine, obtaining good results and symptom control.

Conclusion

Schnitzler syndrome is a rare disease that does not always occur in the age range usually reported in the literature; the diagnosis is essentially of exclusion and the combination of clinical, laboratory, and imaging findings, as well as multidisciplinary collaboration, is essential. Therapeutic management continues to represent a challenge, and the use of corticosteroids, as well as other immunosuppressive drugs, leads to optimal control of symptoms.

Ethical considerations

The case report was performed under the informed consent of the family, according to resolution 8430 of 1993 of the Ministry of Health of Colombia, guaranteeing the confidentiality of the patient's data according to the principles of the Declaration of Helsinki. The participants in this research were only people of legal age according to Colombian legislation, from whom written informed consent was obtained for the collection of information, data analysis, and publication of results, maintaining their anonymity throughout the process.

Conflict of interests

The authors declare that there is no conflict of interest.

Financing

None.

REFERENCES

- Gusdorf L, Lipsker D. Schnitzler syndrome: a review. *Curr Rheumatol Rep*. 2017;19:46, <http://dx.doi.org/10.1007/s11926-017-0673-5>.
- Kim YS, Song YM, Bang CH, Seo HM, Lee JH, Park YM, et al. Schnitzler syndrome: a case report and review of literature. *Ann Dermatol*. 2018;30:483-5, <http://dx.doi.org/10.5021/ad.2018.30.4.483>.
- Nigrovic P. Periodic fever syndromes and other autoinflammatory disease: an overview. *UpToDate*. 2018.
- Herráez Albendea MM, López Rodríguez M, López de la Guía A, Canales Albendea MA. Síndrome de Schnitzler. *Reumatol Clin*. 2013;9:383-5.
- Gusdorf L, Asli B, Barbarot S, Néel A, Masseau A, Puéchal X, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. *Allergy*. 2017;72:177-82, <http://dx.doi.org/10.1111/all.13035>.
- Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. *J Eur Acad Dermatol Venereol*. 2017;31:45-52, <http://dx.doi.org/10.1111/jdv.13847>.
- De Koning HD, Bodar EJ, van der Meer JW, Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. *Semin Arthritis Rheum*. 2007;37:137-48, <http://dx.doi.org/10.1016/j.semarthrit.2007.04.001>.
- Lachmann HJ. Autoinflammatory syndromes as causes of fever of unknown origin. *Clin Med (Lond)*. 2015;15:295-8, <http://dx.doi.org/10.7861/clinmedicine.15-3-295>.
- De Koning HD, Schalkwijk J, Stoffels M, Jongekrijg J, Jacobs JF, Verwiel E, et al. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. *Arthritis Res Ther*. 2015;17:187, <http://dx.doi.org/10.1186/s13075-015-0696-0>.
- Bashir M, Bettendorf B, Hariman R. A rare but fascinating disorder: case collection of patients with Schnitzler syndrome. *Case Rep Rheumatol*. 2018;2018:7041576, <http://dx.doi.org/10.1155/2018/7041576>.
- Palladini G, Merlini G. The elusive pathogenesis of Schnitzler syndrome. *Blood*. 2018;131.
- Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. *Nat Immunol*. 2017;18:832-42, <http://dx.doi.org/10.1038/ni.3777>.
- Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. *Haematologica*. 2013;98:1581-5, <http://dx.doi.org/10.3324/haematol.2013.084830>.